Multiple opiate receptors: Déjà vu all over again

Neuropharmacology

Volumn 47, Issue SUPPL. 1, 2004, Pages 312-323

  Pasternak, Gavril W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Analgesia; MOP; MOR 1; Mu receptor; Naloxonazine; Opioid receptor

Indexed keywords

3 METHYLNALTREXONE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; BETA ENDORPHIN; BETA FUNALTREXAMINE; DELTA OPIATE RECEPTOR; DIAMORPHINE; DYNORPHIN A; ENDOMORPHIN 1; ENDOMORPHIN 2; ENKEPHALIN DERIVATIVE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; FENTANYL; KAPPA OPIATE RECEPTOR; METHADONE; MORPHINE; MORPHINE 6 ACETATE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALOXAZONE; NALOXONAZINE; NALOXONE BENZOYLHYDRAZONE; NALTREXONE DERIVATIVE; OPIATE RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; BINDING AFFINITY; DRUG BINDING SITE; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; MOLECULAR BIOLOGY; MOLECULAR CLONING; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW;

EID: 4644343161     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.07.004     Document Type: Article

References (122)

1. Abbadie C., Gultekin S.H., Pasternak G.W. Immunohistochemical localization of the carboxy terminus of the novel mu opioid receptor splice variant MOR-1C within the human spinal cord. Neuroreport. 11:2000a;1953-1957
2. Abbadie C., Pan Y.-X., Drake C.T., Pasternak G.W. Comparative immunohistochemical distributions of carboxy terminus epitopes from the mu opioid receptor splice variants MOR-1D, MOR-1 and MOR-1C in the mouse and rat central nervous systems. Neuroscience. 100:2000b;141-153
3. Abbadie C., Pan Y.-X., Pasternak G.W. Differential distribution in rat brain of mu opioid receptor carboxy terminal splice variants MOR-1C and MOR-1-like immunoreactivity: evidence for region-specific processing. J. Comp. Neurol. 419:2000c;244-256
4. Abbadie C., Pasternak G.W., Aicher S.A. Presynaptic localization of the carboxy-terminus epitopes of the mu opioid receptor splice variants MOR-1C and MOR-1D in the superficial laminae of the rat spinal cord. Neuroscience. 106:2001;833-842
5. Bare L.A., Mansson E., Yang D. Expression of two variants of the human μ opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett. 354:1994;213-216
6. Baron A., Shuster L., Elefterhiou B.E., Bailey D.W. Opiate receptors in mice: genetic differences. Life Sci. 17:1975;633-640
7. Bolan E.A., Pasternak G.W. Functional analysis of MOR-1 splice variants of the mu opioid receptor gene, Oprm. Synapse. 51:2004;11-18
8. Brown G.P., Yang K., King M.A., Rossi G.C., Leventhal L., Chang A., Pasternak G.W. 3-Methoxynaltrexone, a selective heroin/morphine-6β- glucuronide antagonist. FEBS Lett. 412:1997;35-38
9. Chang K.-J., Cooper B.R., Hazum E., Cuatrecasas P. Multiple opiate receptors: different regional distribution in the brain and differential binding of opiates and opioid peptides. Mol. Pharmacol. 16:1979;91-104
10. Chang A., Emmel D.W., Rossi G.C., Pasternak G.W. Methadone analgesia in morphine-insensitive CXBK mice. Eur. J. Pharmacol. 351:1998;189-191
11. Chen Y., Mestek A., Liu J., Hurley J.A., Yu L. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol. Pharmacol. 44:1993a;8-12
12. Chen Y., Mestek A., Liu J., Yu L. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the μ and δ opioid receptors. Biochem. J. 295:1993b;625-628
13. Cherny N., Ripamonti C., Pereira J., Davis C., Fallon M., McQuay H., Mercadante S., Pasternak G., Ventafridda V. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J. Clin. Oncol. 19:2001;2542-2554
14. Chien C.-C., Pasternak G.W. Selective antagonism of opioid analgesia by a sigma system. J. Pharmacol. Exp. Ther. 271:1994;1583-1590
15. Chien C.-C., Pasternak G.W. (-)-Pentazocine analgesia in mice: interactions with a σ receptor system. Eur. J. Pharmacol. 294:1995a;303-308
16. Chien C.-C., Pasternak G.W. Sigma antagonists potentiate opioid analgesia in rats. Neurosci. Lett. 190:1995b;137-139
17. 3 subtype. J. Pharmacol. Exp. Ther. 251:1989;461-468
18. Creese I., Pasternak G.W., Pert C.B., Snyder S.H. Discrimination by temperature of opiate agonist and antagonist receptor binding. Life Sci. 16:1975;1837-1842
19. Du Y.-L., Elliot K., Pan Y.-X., Pasternak G.W., Inturrisi C.E. A splice variant of the mu opioid receptor is present in human SHSY-5Y cells. Soc. Neurosci. 23:1997;1206
20. Eppler C.M., Hulmes J.D., Wang J.-B., Johnson B., Corbett M., Luthin D.R., Uhl G.R., Linden J. Purification and partial amino acid sequence of a μ opioid receptor from rat brain. J. Biol. Chem. 268:1993;26447-26451
21. Evans C.J., Hammond D.L., Frederickson R.C.A. The opioid peptides. Pasternak G.W. The Opiate Receptors. 1988;23-74 Humana Press, Clifton, NJ
22. Evans C.J., Keith D.E. Jr., Morrison H., Magendzo K., Edwards R.H. Cloning of a delta opioid receptor by functional expression. Science. 258:1992;1952-1955
23. Flores C.M., Mogil J.S. The pharmacogenetics of analgesia: toward a genetically-based approach to pain management. Pharmacogenomics. 2:2001;177-194
24. George S.R., Fan T., Xie Z., Tse R., Tam V., Varghese G., O'Dowd B.F. Oligomerization of mu- and delta-opioid receptors, generation of novel functional properties. J. Biol. Chem. 275:2000;26128-26135
25. Gomes I., Jordan B.A., Gupta A., Trapaidze N., Nagy V., Devi L.A. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J. Neurosci. 20:2000;RC110
26. Hahn E.F., Carroll-Buatti M., Pasternak G.W. Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines. J. Neurosci. 2:1982;572-576
27. 1-binding site. Proc. Natl. Acad. Sci. USA. 93:1996;8072-8077
28. 2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J. Biol. Chem. 271:1996;16384-16392
29. Heyman J.S., Williams C.L., Burks T.F., Mosberg H.I., Porreca F. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J. Pharmacol. Exp. Ther. 245:1988;238-243
30. Houde R.W., Wallenstein S.L. Clinical studies of morphine-nalorphine combinations. Fed. Proc. 15:1956;440-441
31. Hughes J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res. 88:1975;295-308
32. Hughes J., Smith T.W., Kosterlitz H.W., Fothergill L.A., Morgan B.A., Morris H.R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 258:1975;577-579
33. Jones K.A., Borowsky B., Tamm J.A., Craig D.A., Durkin M.M., Dai M., Yao W.J., Johnson M., Gunwaldsen C., Huang L.Y., Tang C., Shen Q., Salon J.A., Morse K., Laz T., Smith K.E., Nagarathnam D., Noble S.A., Branchek T.A., Gerald C. GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature. 396:1998;674-679
34. Kaupmann K., Malitschek B., Schuler V., Heid J., Froestl W., Beck P., Mosbacher J., Bischoff S., Kulik A., Shigemoto R., Karschin A., Bettler B. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature. 396:1998;683-687
35. Kekuda R., Prasad P.D., Fei Y.-J., Leibach F.H., Ganapathy V., Fei Y.J. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem. Biophys. Res. Commun. 229:1996;553-558
36. Kieffer B.L., Befort K., Gaveriaux-Ruff C., Hirth C.G. The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. USA. 89:1992;12048-12052
37. Kolesnikov Y.A., Pan Y.-X., Babey A.M., Jain S., Wilson R., Pasternak G.W. Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: evidence for opposing NO actions on morphine analgesia and tolerance. Proc. Natl. Acad. Sci. USA. 94:1997;8220-8225
38. Kosterlitz H.W., Leslie F.M. Comparison of the receptor binding characteristics of opiate agonists interacting with μ- or κ-receptors. Br. J. Pharmacol. 64:1978;607-614
39. Kosterlitz H.W., Paterson S.J., Robson L.E. Characterization of the kappa-subtype of the opiate receptor in the guinea-pig brain. Br. J. Pharmacol. 73:1981;939-949
40. Kosterlitz H.W., Paterson S.J., Robson L.E. Characterization of the kappa subtype of opiate receptor in the guinea pig brain. Br. J. Pharmacol. 68:1986;333-342
41. Lasagna L., Beecher H.K. Analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. J. Pharmacol. Exp. Ther. 112:1954;356-363
42. 3H]-dihydromorphine in the mouse vas deferens and the myenteric plexus and brain of the guinea pig. Eur. J. Pharmacol. 56:1979;379-383
43. Li S., Zhu J., Chen C., Chen Y.-W., Deriel J.K., Ashby B., Liu-Chen L.-Y. Molecular cloning and expression of a rat kappa opioid receptor. Biochem. J. 295:1993;629-633
44. Ling G.S.F., Pasternak G.W. Spinal and supraspinal opioid analgesia in the mouse: the role of subpopulations of opioid binding sites. Brain Res. 271:1983;152-156
45. Ling G.S.F., Spiegel K., Nishimura S., Pasternak G.W. Dissociation of morphine's analgesic and respiratory depressant actions. Eur. J. Pharmacol. 86:1983;487-488
46. Ling G.S.F., MacLeod J.M., Lee S., Lockhart S.H., Pasternak G.W. Separation of morphine analgesia from physical dependence. Science. 226:1984;462-464
47. Ling G.S.F., Spiegel K., Lockhart S.H., Pasternak G.W. Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J. Pharmacol. Exp. Ther. 232:1985;149-155
48. Ling G.S.F., Simantov R., Clark J.A., Pasternak G.W. Naloxonazine actions in vivo. Eur. J. Pharmacol. 129:1986;33-38
49. Loh H.H., Liu H.C., Cavalli A., Yang W.L., Chen Y.F., Wei L.N. μ Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Mol. Brain Res. 54:1998;321-326
50. Lord J.A.H., Waterfield A.A., Hughes J., Kosterlitz H.W. Endogenous opioid peptides: multiple agonists and receptors. Nature. 267:1977;495-499
51. Luke M.C., Hahn E.F., Price M., Pasternak G.W. Irreversible opiate agonists and antagonists: V. Hydrazone and acylhydrazone derivatives of naltrexone. Life Sci. 43:1988;1249-1256
52. Martin W.R. Opioid antagonists. Pharmacol. Rev. 19:1967;463-521
53. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. The effects of morphine and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197:1976;517-532
54. Matthes H.W.D., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dollé P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature. 383:1996;819-823
55. 1 receptor. Biochem. Pharmacol. 62:2001;349-355
56. Meng F., Xie G.X., Thompson R.C., Mansour A., Goldstein A., Watson S.J., Akil H. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc. Natl. Acad. Sci. USA. 90:1993;9954-9958
57. Mogil J.S., Yu L., Basbaum A.I. Pain genes?: natural variation and transgenic mutants. Annu. Rev. Neurosci. 23:2000;777-811
58. 1 receptor. J. Neurochem. 70:1998;2279-2285
59. Pan Y.-X., Xu J., Bolan E.A., Abbadie C., Chang A., Zuckerman A., Rossi G.C., Pasternak G.W. Identification and characterization of three new alternatively spliced mu opioid receptor isoforms. Mol. Pharmacol. 56:1999;396-403
60. Pan Y.-X., Xu J., Bolan E., Chang A., Mahurter L., Rossi G., Pasternak G.W. Isolation and expression of a novel alternatively spliced mu opioid receptor isoform, MOR-1F. FEBS Lett. 466:2000a;337-340
61. Pan Y.-X., Xu J., Rossi G.C., Xu M.M., Mahurter L., Bolan E.A., Pasternak G.W. Identification and characterization of a novel promoter of a mouse mu opioid receptor gene (MOR-1) that directs alternative splicing and differential expression of eight new variants. Soc. Neurosci. 26:2000b;2097
62. Pan Y.-X., Xu J., Mahurter L., Bolan E.A., Xu M.M., Pasternak G.W. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc. Natl. Acad. Sci. USA. 98:2001;14084-14089
63. Pan Y.-X., Xu J., Mahurter L., Xu M.M., Gilbert A.-K., Pasternak G.W. Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem. Biophys. Res. Commun. 301:2003;1057-1061
64. 1 systems. Regulatory Peptides. 54:1994;219-220
65. Pasternak G.W. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol. Sci. 22:2001a;67-70
66. Pasternak G.W. Insights into mu opioid pharmacology - the role of mu opioid receptor subtypes. Life Sci. 68:2001b;2213-2219
67. Pasternak G.W. The pharmacology of mu analgesics: from patients to genes. Neuroscientist. 7:2001c;220-231
68. Pasternak G.W., Hahn E.F. Long-acting opiate agonists and antagonists: 14-hydroxydihydromorphinone hydrazones. J. Med. Chem. 23:1980;674-677
69. Pasternak G.W., Pan Y.-X. Antisense mapping: assessing the functional significance of genes and splice variants. Meth. Enzymol. 314:2000;51-60
70. Pasternak G.W., Snyder S.H. Identification of a novel high affinity opiate receptor binding in rat brain. Nature. 253:1975a;563-565
71. Pasternak G.W., Snyder S.H. Opiate receptor binding: enzymatic treatments and discrimination between agonists and antagonists. Mol. Pharmacol. 11:1975b;735-744
72. Pasternak G.W., Standifer K.M. Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends Pharmacol. Sci. 16:1995;344-350
73. Pasternak G.W., Goodman R., Snyder S.H. An endogenous morphine like factor in mammalian brain. Life Sci. 16:1975a;1765-1769
74. 3H]opiate agonist binding by divalent cations. Mol. Pharmacol. 11:1975b;478-484
75. Pasternak G.W., Wilson H.A., Snyder S.H. Differential effects of protein-modifying reagents on receptor binding of opiate agonists and antagonists. Mol. Pharmacol. 11:1975c;340-351
76. Pasternak G.W., Childers S.R., Snyder S.H. Naloxazone, long-acting opiate antagonist: effects in intact animals and on opiate receptor binding in vitro. J. Pharmacol. Exp. Ther. 214:1980a;455-462
77. Pasternak G.W., Childers S.R., Snyder S.H. Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors. Science. 208:1980b;514-516
78. Pasternak G.W., Carroll-Buatti M., Spiegel K. The binding and analgesic properties of a sigma opiate, SKF 10,047. J. Pharmacol. Exp. Ther. 219:1981;192-198
79. Pasternak G.W., Bodnar R.J., Clark J.A., Inturrisi C.E. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 41:1987;2845-2849
80. Pasternak, D.A., Pan, L., Xu, J., Yu, R., Xu, M., Pasternak, G.W., Pan, Y.-X., 2004. Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: dissociation of affinity and efficacy. J. Neurochem., in press.
81. Paul D., Pasternak G.W. Differential blockade by naloxonazine of two μ opiate actions: analgesia and inhibition of gastrointestinal transit. Eur. J. Pharmacol. 149:1988;403-404
82. Paul D., Bodnar R.J., Gistrak M.A., Pasternak G.W. Different μ receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur. J. Pharmacol. 129:1989a;307-314
83. Paul D., Standifer K.M., Inturrisi C.E., Pasternak G.W. Pharmacological characterization of morphine-6β-glucuronide, a very potent morphine metabolite. J. Pharmacol. Exp. Ther. 251:1989b;477-483
84. Paul D., Levison J.A., Howard D.H., Pick C.G., Hahn E.F., Pasternak G.W. Naloxone benzoylhydrazone (NalBzoH) analgesia. J. Pharmacol. Exp. Ther. 255:1990;769-774
85. Payne R., Pasternak G.W. Pharmacology of pain treatment. Johnston M.V., MacDonald R., Young A.B. Contemporary Neurology Series: Scientific Basis of Neurologic Drug Therapy. 1992;268-301 Davis, Philadelphia
86. Pert C.B., Snyder S.H. Opiate receptor: demonstration in nervous tissue. Science. 179:1973;1011-1014
87. Pert C.B., Pasternak G.W., Snyder S.H. Opiate agonists and antagonists discriminated by receptor binding in brain. Science. 182:1973;1359-1361
88. 2]-Met- enkephalinamide: a potent, long-lasting synthetic pentapeptide analgesic. Science. 194:1976;330-332
89. Pick C.G., Cheng J., Paul D., Pasternak G.W. Genetic influences in opioid analgesic sensitivity in mice. Brain Res. 556:1991;295-298
90. 3H-naloxone benzoylhydrazone: a reversible kappa and slowly dissociable μ opiate. Mol. Pharmacol. 35:1989;67-74
91. Reith M.E.A., Sershen H., Vadasz C., Lajtha A. Strain differences in opiate receptors in mouse brain. Eur. J. Pharmacol. 74:1981;377-380
92. Roemer D., Buescher H.H., Hill R.C., Pless J., Bauer W., Cardinaux F., Closse A., Hauser D., Huguenin R. A synthetic enkephalin analogue with prolonged parenteral and oral analgesic activity. Nature. 268:1977;547-549
93. Rossi G., Pan Y.-X., Cheng J., Pasternak G.W. Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sci. 54:1994;L375-L379
94. Rossi G.C., Pan Y.-X., Brown G.P., Pasternak G.W. Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6β-glucuronide receptor. FEBS Lett. 369:1995a;192-196
95. Rossi G.C., Standifer K.M., Pasternak G.W. Differential blockade of morphine and morphine-6β-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein α subunits in rats. Neurosci. Lett. 198:1995b;99-102
96. Rossi G.C., Brown G.P., Leventhal L., Yang K., Pasternak G.W. Novel receptor mechanisms for heroin and morphine-6β-glucuronide analgesia. Neurosci. Lett. 216:1996;1-4
97. Rothman R.B., Bykov V., DeCosta B.R., Jacobson A.E., Rice K.C., Brady L.S. Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides. 11:1990;311-317
98. Schuller A.G., King M.A., Zhang J., Bolan E., Pan Y.X., Morgan D.J., Chang A., Czick M.E., Unterwald E.M., Pasternak G.W., Pintar J.E. Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat. Neurosci. 2:1999;151-156
99. Seth P., Leibach F.H., Ganapathy V. Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor. Biochem. Biophys. Res. Commun. 241:1997;535-540
100. Shimomura K., Kamata O., Ueki S., Ida S., Oguri K., Yoshimura H., Tsukamoto H. Analgesic effect of morphine glucuronides. Tohoku J. Exp. Med. 105:1971;45-52
101. 3H]etorphine to rat-brain homogenate. Proc. Natl. Acad. Sci. USA. 70:1973;1947-1949
102. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., Uhl G.R. Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. USA. 94:1997;1544-1549
103. Spiegel K., Kourides I., Pasternak G.W. Prolactin and growth hormone release by morphine in the rat: different receptor mechanisms. Science. 217:1982;745-747
104. Standifer K.M., Chien C.-C., Wahlestedt C., Brown G.P., Pasternak G.W. Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. Neuron. 12:1994;805-810
105. Terenius L. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. Acta Pharmacol. Toxicol. 32:1973;317-320
106. Terenius L., Wahlstrom A. Search for an endogenous ligand for the opiate receptor. Acta Physiol. Scand. 94:1975;74-81
107. Thompson R.C., Mansour A., Akil H., Watson S.J. Cloning and pharmacological characterization of a rat μ opioid receptor. Neuron. 11:1993;903-913
108. Tiseo P.J., Thaler H.T., Lapin J., Inturrisi C.E., Portenoy R.K., Foley K.M. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain. 61:1995;47-54
109. Uhl G.R., Childers S., Pasternak G.W. An opiate-receptor gene family reunion. Trends Neurosci. 17:1994;89-93
110. VonVoightlander P.F., Lahti R.A., Ludens J.H. U50,488: a selective and structurally novel non-mu (kappa) opioid agonist. J. Pharmacol. Exp. Ther. 224:1983;7-12
111. Walker J.M., Berntson G.G., Sandman C.A., Coy D.H., Schally A.V., Kastin A.J. An analog of enkephalin having prolonged opiate-like effects in vivo. Science. 196:1977;85-87
112. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B., Rice K.C. Sigma receptors: biology and function. Pharmacol. Rev. 42:1990;355-402
113. Walker J.R., King M., Izzo E., Koob G.F., Pasternak G.W. Antagonism of heroin and morphine self-administration in rats by the morphine-6β- glucuronide antagonist 3-o-methylnaltrexone. Eur. J. Pharmacol. 383:1999;115-119
114. Wang J.B., Imai Y., Eppler C.M., Gregor P., Spivak C.E., Uhl G.R. μ Opiate receptor: cDNA cloning and expression. Proc. Natl. Acad. Sci. USA. 90:1993;10230-10234
115. White J.H., Wise A., Main M.J., Green A., Fraser N.J., Disney G.H., Barnes A.A., Emson P., Foord S.M., Marshall F.H. Heterodimerization is required for the information of a functional GABA(B) receptor. Nature. 396:1998;679-682
116. Wilson H.A., Pasternak G.W., Snyder S.H. Differentiation of opiate agonist and antagonist receptor binding by protein-modifying reagents. Nature. 256:1975;448-450
117. Wolozin B.L., Nishimura S., Pasternak G.W. The binding of kappa and sigma opiates in rat brain. J. Neurosci. 2:1982;708-713
118. Wolozin B.L., Pasternak G.W. Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc. Natl. Acad. Sci. USA. 78:1981;6181-6185
119. Yoshimura H., Ida S., Oguri K., Tsukamoto H. Biochemical basis for analgesic activity of morphine-6β-glucuronide I: penetration of morphine-6β-glucuronide in the brain of rats. Biochem. Pharmacol. 22:1973;1423-1430
120. Zhu X., Wess J. Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function. Biochemistry. 37:1998;15773-15784
121. Zimprich A., Simon T., Hollt V. Cloning and expression of an isoform of the rat μ opioid receptor (rMOR 1 B) which differs in agonist induced desensitization from rMOR1. FEBS Lett. 359:1995;142-146
122. 2 opioid receptors. Proc. Natl. Acad. Sci. USA. 85:1988;4061-4065